Impact and Mechanisms of Action of BDNF on Neurological Disorders, Cancer, and Cardiovascular Diseases

被引:0
|
作者
Lei, Min [1 ]
Liu, Qiwen [2 ]
Nie, Jinxia [2 ]
Huang, Rongyi [2 ]
Mei, Yan [2 ]
Pan, Dan [2 ]
Chen, Yong [3 ]
Liu, Wu [2 ]
机构
[1] Hubei Univ Sci & Technol, Xianning Med Coll, Hubei Key Lab Diabet & Angiopathy, Xianning, Hubei, Peoples R China
[2] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Basic Med Sci, Hubei Key Lab Diabet & Angiopathy, Xianning, Hubei, Peoples R China
[3] Hubei Univ Sci & Technol, Xianning Cent Hosp, Affiliated Hosp 1, Xianning, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
BDNF; cancer; cardiovascular diseases; neurogenic diseases; neuroregulation; TrkB; NEUROTROPHIC FACTOR ACTIVATION; LONG-TERM POTENTIATION; OXIDATIVE STRESS; NEUROPATHIC PAIN; INFLAMMATORY PAIN; POOR-PROGNOSIS; MAPK PATHWAYS; RECEPTOR TRKB; PLASMA-LEVELS; GROWTH-FACTOR;
D O I
10.1111/cns.70138
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Brain-derived neurotrophic factor (BDNF), which is primarily expressed in the brain and nervous tissues, is the most abundant neurotrophic factor in the adult brain. BDNF serves not only as a major neurotrophic signaling agent in the human body but also as a crucial neuromodulator. Widely distributed throughout the central nervous system (CNS), both BDNF and its receptors play a significant role in promoting neuronal survival and growth, thereby exerting neuroprotective effects. It is further considered as a guiding medium for the functionality and structural plasticity of the CNS. Increasingly, research has indicated the critical importance of BDNF in understanding human diseases. Activation of intracellular signaling pathways such as the mitogen-activated protein kinase pathway, phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, and phospholipase C gamma pathway by BDNF can all potentially enhance the growth, survival, proliferation, and migration of cancer cells, influencing cancer development. The loss of BDNF and its receptor, tropomyosin receptor kinase B, in signaling pathways is also associated with increased susceptibility to brain and heart diseases. Additionally, reduced BDNF levels in both the central and peripheral systems have been closely linked to various neurogenic diseases, including neuropathic pain and psychiatric disorders. As such, this review summarizes and analyzes the impact of BDNF on neurogenic diseases, cancer, and cardiovascular diseases. This study thereby aimed to elucidate its effects on these diseases to provide new insights and approaches for their treatment.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] NEUROLOGICAL DISORDERS IN RENAL DISEASES
    KORCHEMNY, VA
    VRACHEBNOE DELO, 1983, (05): : 58 - 60
  • [22] BDNF Therapeutic Mechanisms in Neuropsychiatric Disorders
    Bazzari, Amjad H.
    Bazzari, Firas H.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [23] Potential therapeutic uses of BDNF in neurological and psychiatric disorders
    Nagahara, Alan H.
    Tuszynski, Mark H.
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (03) : 209 - 219
  • [24] Phytochemicals Targeting BDNF Signaling for Treating Neurological Disorders
    Singh, Alka Ashok
    Katiyar, Shweta
    Song, Minseok
    BRAIN SCIENCES, 2025, 15 (03)
  • [25] Th17 cells and inflammation in neurological disorders: Possible mechanisms of action
    Shi, Yajun
    Wei, Bin
    Li, Lingjun
    Wang, Bin
    Sun, Miao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities
    Shahripour, Reza Bavarsad
    Harrigan, Mark R.
    Alexandrov, Andrei V.
    BRAIN AND BEHAVIOR, 2014, 4 (02): : 108 - 122
  • [28] Mitochondrial Mechanisms and Neurological Disorders
    Gropman, Andrea L.
    NEUROTHERAPEUTICS, 2013, 10 (02) : 185 - 185
  • [29] Potential therapeutic uses of BDNF in neurological and psychiatric disorders
    Alan H. Nagahara
    Mark H. Tuszynski
    Nature Reviews Drug Discovery, 2011, 10 : 209 - 219
  • [30] Mitochondrial Mechanisms and Neurological Disorders
    Andrea L. Gropman
    Neurotherapeutics, 2013, 10 : 185 - 185